These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 9454116)
1. [Crystallization test in patients with head and neck neoplasms]. Kuczkowski J; Zaorski P; Betlejewski A Otolaryngol Pol; 1995; 49 Suppl 20():121-4. PubMed ID: 9454116 [TBL] [Abstract][Full Text] [Related]
2. Crystallization test for the detection of head and neck cancer. Gulati SP; Sachdeva OP; Sachdeva A; Adlakha RP; Kakkar V ORL J Otorhinolaryngol Relat Spec; 1994; 56(5):283-6. PubMed ID: 7970613 [TBL] [Abstract][Full Text] [Related]
3. [Alpha-fetoprotein--diagnostic utility in squamous cell carcinoma of the head and neck]. Adamiak G; Ligeziński A; Jurkiewicz D; Hermanowski M; Konieczna M Pol Merkur Lekarski; 2001 Oct; 11(64):320-2. PubMed ID: 11770310 [TBL] [Abstract][Full Text] [Related]
4. CYFRA 8/18 in head and neck cancer. Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. Cosway B; Paleri V; Wilson J J Laryngol Otol; 2015 Nov; 129(11):1046-52. PubMed ID: 26429303 [TBL] [Abstract][Full Text] [Related]
6. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck]. González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679 [TBL] [Abstract][Full Text] [Related]
7. [Clinical value of head and neck tumor markers]. Gascón Vilaplana P Med Clin (Barc); 2007 Dec; 129(20):775-6. PubMed ID: 18093479 [No Abstract] [Full Text] [Related]
8. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093 [TBL] [Abstract][Full Text] [Related]
9. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946 [TBL] [Abstract][Full Text] [Related]
10. Erratum: Prognostic Value of Routine Blood Markers in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). JCO Glob Oncol; 2024 Aug; 10():e2400368. PubMed ID: 39213465 [No Abstract] [Full Text] [Related]
11. A new prognostic indicator for head and neck cancer--p53 serum antibodies? Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224 [TBL] [Abstract][Full Text] [Related]
12. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719 [TBL] [Abstract][Full Text] [Related]
13. Circulating markers in squamous cell carcinoma of the head and neck: a review. Rassekh CH; Johnson JT; Eibling DE Eur J Cancer B Oral Oncol; 1994 Jan; 30B(1):23-8. PubMed ID: 9135969 [TBL] [Abstract][Full Text] [Related]
14. Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease. Tanus-Santos JE; Gerlach RF Int J Cancer; 2006 Feb; 118(3):789; author reply 790. PubMed ID: 16094623 [No Abstract] [Full Text] [Related]
15. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Brakenhoff RH; Stroomer JG; ten Brink C; de Bree R; Weima SM; Snow GB; van Dongen GA Clin Cancer Res; 1999 Apr; 5(4):725-32. PubMed ID: 10213205 [TBL] [Abstract][Full Text] [Related]
16. p53 autoantibodies as tumor marker in head and neck squamous cell cancer. Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322 [TBL] [Abstract][Full Text] [Related]
17. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Tan A; Adelstein DJ; Rybicki LA; Saxton JP; Esclamado RM; Wood BG; Lorenz RR; Strome M; Carroll MA Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):435-40. PubMed ID: 17515501 [TBL] [Abstract][Full Text] [Related]
18. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Linkov F; Lisovich A; Yurkovetsky Z; Marrangoni A; Velikokhatnaya L; Nolen B; Winans M; Bigbee W; Siegfried J; Lokshin A; Ferris RL Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):102-7. PubMed ID: 17220337 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas. Nunes DN; Kowalski LP; Simpson AJ Int J Cancer; 2001 Apr; 92(2):214-9. PubMed ID: 11291048 [TBL] [Abstract][Full Text] [Related]
20. Commentary re: Q-T Le et al, identification of osteopontin as a prognostic marker for head and neck squamous cell carcinomas. clin cancer res, 9: 31-32, 2003. Denhardt DT Clin Cancer Res; 2003 Jan; 9(1):31-2. PubMed ID: 12538448 [No Abstract] [Full Text] [Related] [Next] [New Search]